Mechanism of Action: Estrogen Receptor Agonists

Drugs with Mechanism of Action: Estrogen Receptor Agonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907-002	Dec 28, 2006		DISCN	Yes	No
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907-001	Nov 18, 1998	AB	RX	Yes	Yes
Bayer Hlthcare	ANGELIQ	drospirenone; estradiol	TABLET;ORAL	021355-001	Feb 29, 2012		RX	Yes	No	8,906,890		Y
Bayer Hlthcare	ANGELIQ	drospirenone; estradiol	TABLET;ORAL	021355-002	Sep 28, 2005		RX	Yes	Yes
Mayne Pharma	ANNOVERA	ethinyl estradiol; segesterone acetate	RING;VAGINAL	209627-001	Aug 10, 2018		RX	Yes	Yes	10,918,649		Y

Estrogen Receptor Agonists Market Analysis and Financial Projection

The estrogen receptor agonist market is experiencing robust growth driven by increasing therapeutic applications and advancements in targeted therapies. Valued at $2.3 billion in 2022, the market is projected to reach $4.8 billion by 2030 (9.6% CAGR)[1], with alternative estimates suggesting even higher growth to $12 billion by 2037 (7.6% CAGR)[4], reflecting variations in market segmentation and regional analysis.

Market Dynamics

Key Growth Drivers:

• Rising Disease Burden:
  • 17.9 million annual cardiovascular deaths globally[4]
  • 1.2 billion postmenopausal women worldwide by 2030[4]
  • 70% of breast cancers are ER+[10], driving demand for targeted therapies

Therapeutic Innovations:

• Transition from injectable (e.g., fulvestrant) to oral SERDs like FDA/EMA-approved elacestrant[3][10]
• Novel pipeline candidates:
  • Roche's giredestrant (Phase III persistence trial data expected 2025)[3]
  • Lilly's imlunestrant in endometrial cancer trials[3]

Market Segmentation:	Segment	Dominant Category	Rationale
Administration	Oral (65% share)	Lower cost, faster absorption[4][8]
Distribution	Hospital Pharmacies	Physician-prescribed nature[8]
Geography	Asia-Pacific	Aging population (1/4 >60 by 2050)[4]

Patent Landscape

Key Innovations:

1. SERD Formulations:

   • Duke University's US-10071066-B2 for ER+ brain cancer treatment[2][12]
   • Atossa Therapeutics' sustained-release endoxifen patent (US-12,201,591)[5]

2. Delivery Systems:

   • TherapeuticsMD's hormone replacement combo (US-10206932-B2) with C6-C12 oil solubilization[16]

3. Novel Targets:

   • ERβ agonists for fibrotic conditions (WO2020160225A1)[13]
   • Covalent antagonists (SERCAs) with irreversible ER binding[10]

Competitive Activity:

• 91 new SERD/SERCA patent applications from 32 companies (2021-2023)[10]
• US leads patent filings (52% from universities/companies)[7], followed by China focusing on fusion proteins[7]

Strategic Challenges:

• Patent cliffs creating generic entry opportunities (e.g., faslodex generics)[3]
• PTAB invalidations impacting specific claims (e.g., Atossa's '334 patent)[5]

---

Regional Developments

North America:

• Projected 9% CAGR through 2029[6]
• Dominated by cancer R&D (41% of global pharma trials)[17]

Europe:

• 75 million osteoporosis patients driving SERM demand[17]

Emerging Markets:

• India/China seeing 12% annual growth in hormone therapies[16]

---

Future Outlook:
The market will likely bifurcate into:

1. Premium Oral Therapies: Projected $3B revenue from ORSERDU/camizestrant by 2034[3]
2. Cost-Effective Generics: Accelerating post-2025 as key patents expire

Ongoing Phase III trials for 15+ novel ER agonists and combination therapies suggest sustained innovation, though inter-individual response variability remains a treatment challenge[14].

"The shift to oral SERDs represents a paradigm change in endocrine therapy – we're moving from disease management to precision targeting of resistance mechanisms." [10]

References

1. https://sites.google.com/view/viewglobalmarket/others/estrogen-receptor-agonist-market
2. https://pubchem.ncbi.nlm.nih.gov/patent/US-10071066-B2
3. https://www.globenewswire.com/news-release/2024/10/02/2957237/0/en/SERD-Market-is-Predicted-to-Exhibit-Remarkable-Growth-Owing-to-the-Usage-of-Faslodex-in-Combination-Strong-Performance-of-ORSERDU-and-Speedy-Progress-of-Other-Oral-SERDs-During-the.html
4. https://www.researchnester.com/reports/estrogen-receptor-agonist-market/4982
5. https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-responds-ptab-ruling-us-patent-no-11572334
6. https://www.databridgemarketresearch.com/reports/global-estrogen-receptor-modulators-market
7. https://www.scirp.org/html/35040.html
8. https://www.researchnester.com/reports/estrogen-receptor-agonist-market/4982/market-analysis
9. https://patents.google.com/patent/EP1086692A2/en
10. https://pubmed.ncbi.nlm.nih.gov/38836316/
11. https://www.coherentmarketinsights.com/market-insight/estrogen-blockers-market-5995
12. https://downloads.regulations.gov/FDA-2023-E-3224-0005/attachment_1.pdf
13. https://patents.google.com/patent/WO2020160225A1/en
14. https://academic.oup.com/humupd/article/24/5/577/5035760
15. https://www.drugpatentwatch.com/p/generic-api/estradiol
16. https://pubchem.ncbi.nlm.nih.gov/patent/US10206932
17. https://www.qyresearch.com/reports/3579108/estrogen-receptor-modulators